Showing 71-80 of 1043 results for "".
SMA Experience: Episode 2
https://practicalneurology.com/diseases-diagnoses/neuromuscular/sma-experience-episode-2/30081/Neuromusclar disease expert Diana Bharucha-Goebel, MD, PhD chats with Traci High, mother of two patients with SMA about how the SMA treatment landscape, and her childens' lives, have changed over the past 15 years.Detecting Multiple Sclerosis Earlier: PRLs and the Evolving McDonald Diagnostic Criteria
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/detecting-multiple-sclerosis-earlier-prls-and-the-evolving-mcdonald-diagnostic-criteria/54390/This episode explores new evidence showing that paramagnetic rim lesions (PRLs) are highly prevalent early in multiple sclerosis (MS) and can differentiate MS from mimics with striking accuracy. Daniel Ontaneda, MD, PhD, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, and Pascal Sati, PhUpdates in Bruton Tyrosine Kinase Inhibition for Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/updates-in-bruton-tyrosine-kinase-inhibition-for-multiple-sclerosis/31975/Ongoing clinical trials will elucidate potential advantages and safety of these novel medications for future treatment of multiple sclerosis.- Picturing Freedom of Movement: A Practical Approach to Alleviating Spasticityhttps://practicalneurology.com/columns/practice-management/picturing-freedom-of-movement-a-practical-approach-to-alleviating-spasticity/31370/Spasticity, characterized by a velocity-dependent increase in muscle tone, significantly limits passive muscle stretch and limb movement. It arises from disruptions in descending inhibitory spinal motor pathways, leading to overactive alpha motor neurons. Common causes include central nervous system
Bionic Breakout: Robotic-Assisted Therapy Is Evolving
https://practicalneurology.com/columns/practice-management/bionic-breakout-robotic-assisted-therapy-is-evolving/30726/Robotic-assisted therapy has made significant strides in the past 15 years. Will it overtake conventional physical therapy?- Making the Switch: When and How to Step-Up MS Therapyhttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN1108MS-pdf/30974/Advancements and Considerations in Multiple Sclerosis TherapeuticsOver the past quarter-century, Multiple Sclerosis (MS) treatment has evolved rapidly, marked by the FDA approval of six disease-modifying therapies (DMTs) with several more in development. This acceleration contrasts with the decade-l
- Achieving Proper Balance in Combination Therapy for Alzheimer'shttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0107ComboFea-pdf/31224/Optimizing Alzheimer's Disease Management: Current Therapies and Future DirectionsAlzheimer’s disease (AD) remains a formidable challenge in neurology, significantly impacting patients and their caregivers from mild to advanced stages. While a definitive cure is yet to be discovered, existing therap
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31332/In the realm of neurology, demonstrating patient health improvements necessitates robust qualitative measurements. Clinicians often rely on tools such as MRI comparisons, seizure frequency assessments, and evaluations of Parkinson’s “off” times to establish a baseline against which future treatments
- Will You Be the Last Physician on Your Block to Offer Botox?https://practicalneurology.com/columns/practice-management/will-you-be-the-last-physician-on-your-block-to-offer-botox/31384/Botox’s Expanding Role in Neurology: A Future for Headache ManagementBotox, traditionally renowned for its cosmetic applications, is increasingly becoming integral to neurological practices, particularly in headache and migraine management. As of October 2005, Practical Neurology highlighted Botox’s
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/0105-pain-management-pdf/31506/Recent developments over the past quarter have prompted significant reconsideration of the FDA’s approach to approving and monitoring new pain medications, particularly COX-2 selective anti-inflammatory agents. The catalyst for this shift was Merck’s global withdrawal of rofecoxib (Vioxx) in Septemb